Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar;86(3):581-589.
doi: 10.1016/j.jaad.2021.06.878. Epub 2021 Jul 9.

Comparison of two-year treatment adherence, persistence, discontinuation, reinitiation, and switching between psoriasis patients treated with ixekizumab or secukinumab in real-world settings

Andrew Blauvelt  1 , Nianwen Shi  2 , Najwa Somani  3 , Russel Burge  4 , Baojin Zhu  3 , Terri L Ridenour  3 , Carolyn R Lew  2 , Nicole M Zimmerman  2 , Bilal Atiya  3 , Mwangi J Murage  5
Affiliations

Comparison of two-year treatment adherence, persistence, discontinuation, reinitiation, and switching between psoriasis patients treated with ixekizumab or secukinumab in real-world settings

Andrew Blauvelt et al. J Am Acad Dermatol. 2022 Mar.

Abstract

Background: Real-world data on long-term treatment patterns associated with interleukin-17A inhibitors in plaque psoriasis are lacking.

Objective: To compare ixekizumab or secukinumab treatment patterns over a 24-month period among plaque psoriasis patients.

Methods: Adult patients with psoriasis who had 1 or more claims for ixekizumab or secukinumab between March 1, 2016, and October 31, 2019, and with 24 months of follow-up after starting treatment were identified from IBM MarketScan claims databases. Inverse probability of treatment weighting and multivariable models were employed to balance cohorts and estimate the risks of nonpersistence, discontinuation, and switching and odds of highly adherent treatment (proportion of days covered ≥ 80%).

Results: A total of 471 ixekizumab and 990 secukinumab users were included. Compared to secukinumab, ixekizumab use was associated with a 20% lower risk of nonpersistence (hazard ratio, 0.80; 95% CI, 0.70-0.92), a 17% lower risk of discontinuation (hazard ratio, 0.83; 95% CI, 0.72-0.96), and a 42% higher odds of being highly adherent to treatment (odds ratio, 1.42; 95% CI, 1.12-1.80). No difference in risk of switching was observed (hazard ratio, 0.83; 95% CI, 0.68-1.01).

Limitations: Disease severity and clinical outcomes were unavailable.

Conclusion: Over 24 months, ixekizumab users exhibited better persistence and adherence, and a lower risk of discontinuation than secukinumab users in real-world settings.

Keywords: dosing; ixekizumab; psoriasis; secukinumab; treatment adherence; treatment discontinuation; treatment persistence; treatment reinitiation; treatment switching.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest Dr Blauvelt had received honoraria as a scientific adviser/clinical study investigator from AbbVie, Almirall, Arena, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Eli Lilly and Company, Evommune, Forte, Galderma, Incyte, Janssen, Leo, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB Pharma, but none related to this work. Drs Shi and Lew and Author Zimmerman are employees of IBM Watson Health, which was compensated by Eli Lilly and Company for conducting this research. Drs Somani, Burge, Zhu, Atiya, and Murage, and Author Ridenour are employees of Eli Lilly and Company and hold stock in Eli Lilly and Company.